Lung cancer can be treated using various methods, including surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, etc. Treatment depends on the type and stage of the cancer. For example, surgery can be used to treat early-stage non-small cell lung cancer, and chemotherapy is often used to treat small cell lung cancer. In addition, lung cancer is often treated with multiple therapies, which is called multimodal therapy.
|
Chemotherapy Drugs |
|
| Targeted Therapy |
|
|
| Immunotherapies |
|
Lung cancer diseases and their therapy development have certain market characteristics, which is why Alfa Cytology focuses on the preclinical development of lung cancer therapies.
High Incidence and Mortality
Unmet Medical Needs and Market Potential
Advances in Personalized Therapy
Breakthrough in Immunotherapy
The lung cancer therapy market is large and there is significant potential for economic returns in developing effective drugs/therapies. Therefore, there are a lot of pipelines under development
| Company | Drug/Therapy | Target |
| Roche | Alecensa | ALK |
| AstraZeneca | Durvalumab | PD-L1 |
| Novartis | Capmatinib | MET |
The development of new therapies for lung cancer is of great significance, which can not only improve the survival rate and quality of life but also promote the progress of medical science and technology, which has important clinical, economic, and social significance. Alfa Cytology provides one-stop pre-clinical development services for lung cancer therapies. However, according to the needs of the project, the modular services can also be customized.
To overcome the difficulties and challenges of lung cancer treatment, Alfa Cytology focuses on the development of novel therapies for lung cancer, including but not limited to the following.
There are also some differences in the development process for different therapies, but Alfa Cytology has scientists with various specialties to provide you with tailored development services.
Target Identification and Verification
Identify molecular targets associated with the development and progression of lung cancer.
Lead Compound Screening
To screen out potentially active lead compounds from the compound library.
Lead Compound Optimization
To optimize the pharmacodynamics, pharmacokinetics and safety of lead compounds.
Preclinical Studies
To evaluate the efficacy, pharmacokinetics and safety of the optimized compound.
Target Identification and Verification
Identify specific antigen or molecular targets associated with lung cancer.
Antibody Discovery
Generate candidate antibodies against the target.
Antibody Engineering and Optimization
Optimize the pharmacodynamics, pharmacokinetics and stability of antibodies.
In Vitro Functional Verification
To evaluate the biological activity and specificity of antibodies.
In Vivo Evaluation
To evaluate the antitumor activity of the antibody in animal models.
Safety Assessment
To evaluate the toxicity and safety of antibodies.
Production Process Development
Establish a stable, scalable antibody production process.
Target Identification and Verification
Use genomics, proteomics, and bioinformatics techniques to screen and validate potential targets.
Cell Type Selection
Commonly used cell types include T cells, NK cells, stem cells, etc.
Cell Engineering and Modification
To genetically engineer selected cells to have anti-tumor activity.
Preclinical Studies
To evaluate the efficacy, pharmacokinetics and safety of the optimized compound.
Safety Assessment
Acute toxicity and repeated dose toxicity tests were performed.
Quality Control and Stability Studies
To ensure the quality consistency and stability of cell products.
Antigen Screening and Validation
To identify specific antigens associated with lung cancer.
Vaccine Design
Select the appropriate vaccine type based on the antigen characteristics, such as peptide vaccine and RNA vaccine.
In Vitro Functional Verification
To evaluate the immunogenicity and specificity of the vaccine.
In Vivo Immunological Evaluation
To evaluate the immune response and antitumor effect of the vaccine in animal models.
PK and PD Studies
Pharmacokinetic (PK) and pharmacodynamic (PD) studies
In the development of lung cancer therapies, advanced instruments and equipment as well as professional project experience are often required to support every link from basic research to preclinical development. Alfa Cytology has a variety of professional technology platforms to ensure the efficiency of research and the reliability of data.
Multi-omics analysis: Integration of genomic, transcriptomic, proteomic and metabolomic analyses to further analyze the molecular mechanisms of lung cancer.
Biomarker discovery: Identification of potential diagnostic, prognostic, and therapeutic targets through high-throughput screening and data analysis.
Do you support personalized therapy development?
Yes, Alfa Cytology supports the development of personalized therapy options based on patient-specific data, including genomic analysis and customized drug screening.
How long does data analysis and report delivery take?
The timing of data analysis and report delivery depends on the complexity and size of the project and is usually completed within 2-4 weeks after the completion of the experiment.
Will follow-up support be provided after project completion?
Yes, Alfa Cytology offers support services such as technical consultation, data interpretation, and suggestions for further research after completing the project.
For research use only.
